Comparison Chart Alumis Inc.

Stocks

ALMS

US0223071020

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-21 EDT			5-day change	1st Jan Change
6.810 ^USD	+1.64%		+12.38%	-30.23%

10-09	Alumis Inc. Announces New Envudeucitinib Data From The ONWARD Phase 3 Clinical Program	CI
10-09	Alumis Says Phase 3 Data From Plaque Psoriasis Program Reiterate Treatment's Potential as 'Leading' Oral Therapy	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	ALUMIS INC.	Bio Therapeutic Drugs	+1.64%	+12.38%	-30.23%	+46.77%	-	867M